

# ANKTIVA® is indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.

The unique action of ANKTIVA activates the body's natural immune system by proliferating natural killer cells, killer T Cells and memory T Cells to drive durable T Cell memory and durable responses.



### **Prolonged Duration of Response**


Range of Duration of Response

0.0 to 47+ Months<sup>12</sup>

and Ongoing

Represents the Upper Limit of the Range of Duration





Activating the innate and adaptive immune system without activation of immunosuppressive T Regs

## **ANKTIVA MOA Harnessing Nature's Immune System**


ANKTIVA synergizes with BCG activating innate (NK) and adaptive (T Cell) immune memory – to overcome T Cell immune evasion<sup>1,3</sup>

Activation of DC with PAMPs and DAMPs

ANKTIVA: Mimicking Nature's Mechanism of Action ANKTIVA: Unleashing the Power of the Body'sImmune System – The Triangle Offense ANKTIVA: Harnessing the Power of the IL-15 Receptor Alpha – The CD8+ Memory T Cell

# What happens in our bodies now:

BCG activates T Cells & promotes release of cytokines such as IL-15



"Nature's Cancer Vaccine" Antigen presenting cells educate T Cells & stimulate NK Cells

### ANKTIVA Mechanism of Action


IL-15 Receptor Alpha Fusion Protein with IL-15



ANKTIVA, Mimicking the Body's Immune System IL-15 Receptor Alpha / IL-15 Interaction

### Triangle Offense


NK, CD8+ T, CD4+ T Helper Cells Complete Response



The Triangle Offense of Natural Killer Cells, CD8+ Killer T Cells and CD4+ Helper T Cells

### Memory Killer T Cell

Bladder Cancer Specific CD8+ Memory T Cells Long Duration of CR with a Range of 0-47 Months & Ongoing to Date



Expansion of memory T Cells with Duration of Complete Response 0-47 Months & Ongoing to Date



Open your camera and point your smart device at the QR code to access Anktiva.com

### **INDICATION AND IMPORTANT SAFETY INFORMATION**

INDICATION AND USAGE: ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. WARNINGS AND PRECAUTIONS: Risk of Metastatic Bladder Cancer with Delayed Cystectomy. Delaying cystectomy can lead to the development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after a second induction course of ANKTIVA with BCG, reconsider cystectomy. DOSAGE AND ADMINISTRATION: For Intravesical Use Only. Do not administer by subcutaneous or intravenous routes. Instill intravesically only after dilution. Total time from vial puncture to the completion of the intravesical instillation should not exceed 2 hours. USE IN SPECIFIC POPULATIONS: Pregnancy: May cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ADVERSE REACTIONS: The most common (≥15%) adverse reactions, including laboratory test abnormalities, are increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills and pyrexia.

For more information about ANKTIVA, please see the Full Prescribing Information at www.Anktiva.com.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit <a href="https://www.FDA.gov/medwatch">www.FDA.gov/medwatch</a> or call 1-800-332-1088. You may also contact ImmunityBio at 1-877-ANKTIVA (1-877-265-8482).

- 1. ANKTIVA Prescribing Information. ImmunityBio, Inc.; 2024.
- 2. Based on 48 patients that achieved a complete response at any time; reflects period from the time complete response was achieved. ANKTIVA Prescribing Information, Table 3. ImmunityBio, Inc.; 2024.
- 3. Han KP, et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine. 2011 Dec; 56(3):804-10. doi: 10.1016/j.cyto.2011.09.028.

